Loading clinical trials...
Loading clinical trials...
Evaluation of the Effect of Exisulind on the Duration of the "Off-Treatment" Interval on Patients With Biochemical Relapse of Prostate Cancer Who Are Treated With Intermittent Androgen Suppression (ADT)
Conditions
Interventions
Exisulind
luteinizing hormone-releasing hormone (LHRH) agonist
+1 more
Locations
1
United States
Seattle Cancer Care Alliance
Seattle, Washington, United States
Start Date
March 12, 2002
Primary Completion Date
October 1, 2011
Completion Date
October 1, 2011
Last Updated
August 7, 2018
NCT06844383
NCT06926283
NCT07177937
NCT06594926
NCT05919264
NCT07004582
Lead Sponsor
University of Washington
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions